ArticleAmerican journal of cancer research2024
Predict value of tumor markers combined with interleukins for therapeutic efficacy and prognosis in ovarian cancer patients.
Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Abnormal adnexal uptake inJournal of ovarian research · 2026Article
- Utility of a Multimodal Biomarker Panel and Serum Proapoptotic Activity to Refine Diagnosis of Ovarian Adnexal Masses.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is the most prevalent and fatal malignancy of the female reproductive system, with the majority of patients diagnosed at an advanced stage due to the lack of early screening. Despite surgery and chemotherapy being the standard treatments, overall survival rates have not improved significantly, highlighting the need for new biomarkers for therapeutic efficacy and prognostic evaluation. This study aimed to clarify the application value of tumor markers (TMs), including carbohydrate antigen 125 (CA125), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA), combined with interleukins (ILs), such as IL-1β, IL-2, IL-6, IL-8, and IL-10, in the evaluation of therapeutic efficacy and prognosis of OC, and to establish a prediction model. A retrospective analysis was conducted on 184 OC patients treated at the Affiliated Hospital of Henan University of Traditional Chinese Medicine from February 2020 to February 2023. Serum levels of CA125, AFP, and CEA were quantified by chemiluminescence immunoassay, and ILs by enzyme-linked immunosorbent assays. Significant decreases in CA125, AFP, CEA, IL-1β, IL-2, IL-6, and IL-10 levels were observed after treatment (all P<0.001), while IL-8 levels showed no significant change (P=0.597). The death group exhibited notably higher levels of CA125, IL-6, and IL-8 than the survival group (all P<0.001). Cox regression analysis identified CA125, IL-8, histological grading, ascites, intravascular tumor thrombus, and International Federation of Gynecology and Obstetrics (FIGO) staging as independent prognostic factors. The Nomogram model based on these factors showed strong predictive ability in predicting patient mortality with an area under the curve (AUC) of 0.756. In conclusion, the combination of TMs and ILs is valuable in evaluating therapeutic efficacy and prognosis in OC. Dynamic monitoring of CA125, IL-6, and IL-8 can guide clinical treatment adjustments, improving diagnostic accuracy and prognosis reliability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.